India Pharma Patent Cliff 2030: Beyond Generics to Biosimilars
Over $300 billion in global drug revenue loses exclusivity by 2030. India's generic base is well placed, but the real opportunity lies in complex generics, biosimilars, and API localisation. Here is w
Read article